Subjective Well-being in Patients with Schizophrenia Treated with Atypical Antipsychotics: The Impact of Psychopathology and Adverse Drug Effects

참고문헌 (53)

1. Awad AG, "A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation", Qual Life Res, 6, pp.21~26 (1997)
2. Naber D, "Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs", Schizophr Res, 50, pp.79~88 (2001)
3. Lambert M, "Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia", J Clin Psychiatry, 67, pp.1690~1697 (2006)
4. Lambert M, "Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life", CNS Drugs, 18(2), pp.5~17 (2004)
5. Naber D, "A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables", Int Clin Psychopharmacol, 10(3), pp.133~138 (1995)
6. Awad AG, "Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome", Int Clin Psychopharmacol, 1(2), pp.55~59 (1996)
7. Kim JH, "Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.301~305 (2006)
8. Bow-Thomas CC, "Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization", Psychiatry Res, 86, pp.131~142 (1999)
9. Huppert JD, "Quality of life in schizophrenia: contributions of anxiety and depression", Schizophr Res, 51, pp.171~180 (2001)
10. Ritsner M, "Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients", J Clin Psychiatry, 61, pp.880~889 (2000)
11. Lasalvia A, "Subjective quality of life: its relationship with clinician-rated and patient-rated psychopathology. The South-Verona Outcome Project 6", Psychother Psychosom, 71, pp.275~284 (2002)
12. Fitzgerald PB, "Subject and observer-rated quality of life in schizophrenia", Acta Psychiatr Scand, 103, pp.387~392 (2001)
13. Voruganti LN, "Quality of life measurement during antipsychotic drug therapy of schizophrenia", J Psychiatry Neurosci, 22, pp.267~274 (1997)
14. Kemmler G, "Subjective quality of life of schizophrenic patients. Effect of treatment setting, psychopathology and extrapyramidal motor drug effects", Psychiatr Prax, 26, pp.9~15 (1999)
15. Ritsner M, "The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study", Eur Neuropsychopharmacol, 12, pp.31~38 (2002)
16. Browne S, "Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia", Acta Psychiatr Scand, 94, pp.118~124 (1996)
17. Larsen EB, "Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics", Acta Psychiatr Scand, 93, pp.381~388 (1996)
18. Awad AG, "Quality of life of schizophrenic patients on medications and implications for new drug trials", Hosp Community Psychiatry, 43, pp.262~265 (1992)
19. American Psychiatric Association, "Diagnostic and statistical manual of mental disorder. 4th ed" (1994), American Psychiatric Association
20. Owens DGC, "A guide to the extrapyramidal side-effects of antipsychotic drugs" (1999), Cambridge University Press
21. Kim JH, "Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders", Mov Disord, 17, pp.1354~1359 (2002)
22. de Haan L, "Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale", Psychopharmacology (Berl), 162, pp.24~28 (2002)
23. Naber D, "Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia", Acta Psychiatr Scand, 111, pp.106~115 (2005)
24. Yoon JS, "The development of a Korean modification of the scale to measure subjective well-being under neuroleptic treatment (KmSWN)", J Korean Neuropsychiatr Assoc, 39, pp.987~998 (2000)
25. Kay SR, "Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
26. Bell MD, "Five-component model of schizophrenia: assessing the factorial invariance of the positive and negative syndrome scale", Psychiatry Res, 52, pp.295~303 (1994)
27. Whitehorn D, "Multiple dimensions of recovery in early psychosis", Int Rev Psychiatry, 14, pp.273~283 (2002)
28. Day JC, "A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients", Br J Psychiatry, 166, pp.650~653 (1995)
29. Voruganti L, "Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life", Schizophr Res, 43, pp.135~145 (2000)
30. Mutsatsa SH, "Clinical correlates of early medication adherence: west london first episode schizophrenia study", Acta Psychiatr Scand, 108, pp.439~446 (2003)
31. Barbui C, "Sex differences in the subjective tolerability of antipsychotic drugs", J Clin Psychopharmacol, 25, pp.521~526 (2005)
32. Jung HY, "Liverpool university neuroleptic side-effect rating scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia", Hum Psychopharmacol, 20, pp.41~45 (2005)
33. Shirzadi AA, "Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome", Harv Rev Psychiatry, 14, pp.152~164 (2006)
34. Woods SW, "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)
35. Barrett SL, "Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers", J Psychopharmacol, 18, pp.156~172 (2004)
36. Leucht S, "New generation antipsychotics versus low-potency conventional anti-psychotics: a systematic review and meta-analysis", Lancet, 361, pp.1581~1589 (2003)
37. 김종훈, "비정형 항정신병약물을 투여 중인 정신분열병 환자의 주관적 삶의 질 : 정신병리, 약물 부작용 및 약물에 대한 주관적 반응과의 관련성", 신경정신의학, 42(2) (2003), 대한신경정신의학회
38. Gaite L, "Quality of life in patients with schizophrenia in five European countries: the EPSILON study", Acta Psychiatr Scand, 105, pp.283~292 (2002)
39. Hofer A, "Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects", J Clin Psychiatry, 65, pp.932~939 (2004)
40. Koivumaa-Honkanen HT, "Correlates of life satisfaction among psychiatric patients", Acta Psychiatr Scand, 94, pp.372~378 (1996)
41. Norman RM, "Stressful life events and schizophrenia. I: a review of the research", Br J Psychiatry, 162, pp.161~166 (1993)
42. Tarsy D, "Effects of newer antipsychotics on extrapyramidal function", CNS Drugs, 16, pp.23~45 (2002)
43. Shirzadi AA, "Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome", Harv Rev Psychiatry, 14, pp.152~164 (2006)
44. Kane JM, "Akathisia: an updated review focusing on second-generation antipsychotics", J Clin Psychiatry, 70, pp.627~643 (2009)
45. Van Putten T, "Subjective response to antipsychotic drugs", Arch Gen Psychiatry, 38, pp.187~190 (1981)
46. Hansen L, "A critical review of akathisia, and its possible association with suicidal behaviour", Hum Psychopharmacol, 16, pp.495~505 (2001)
47. Hansen L, "Akathisia as a risk factor for suicide", Br J Psychiatry, 188, pp.192~ (2006)
48. Lindströ0m LH, "Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs", Acta Psychiatr Scand Suppl, 380, pp.74~76 (1994)
49. The NIDS Working Group, "Neuroleptic-induced deficit syndrome (NIDS)", J Clin Psychiatry, 54, pp.493~500 (1993)
50. Voruganti LP, "Brain imaging research on subjective responses to psychotropic drugs", Acta Psychiatr Scand Suppl, 427, pp.22~28 (2005)
51. Gerlach J, "Subjective experience and mental side-effects of antipsychotic treatment", Acta Psychiatr Scand Suppl, 395, pp.113~117 (1999)
52. Barnes TRE, "Antipsychotic drugs and their side-effects" (1993), Academic Press
53. Ritsner M, "Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study", J Clin Psychopharmacol, 24, pp.582~591 (2004)

관련 논문AI추천